Trade Alerts, Monday December 15, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Mon Dec 15th - #SMX #PCLA #ORKT #MIGI #LEXX #GOVX #GLXG #FBLG #EPSM #SNSE #MNTS #IRBT #ATOS #ALBT - More: crystalequityresearch.com/trade-alerts... - #smallcap

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30,

#SNSE Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/SNSE/sensei-biother...

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value Sensei Biotherapeutics (Nasdaq: SNSE) announced on October 30, 2025 that its Board has decided to discontinue development of solnerstotug and has initiated a comprehensive strategic review to maximize shareholder value.The company said it is evaluating options including asset sales, licensing, collaborations, a sale of the company, merger, business combination, or an orderly wind-down. Sensei expects a workforce reduction to preserve cash and will retain a small team to support the strategic process, regulatory and reporting obligations, and an orderly wind-down of the Phase 1/2 trial. No definitive timeline or assurance of a transaction was provided.

#SNSE Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

www.stocktitan.net/news/SNSE/sensei-biother...

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Sensei Biotherapeutics (NASDAQ:SNSE) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead candidate solnerstotug showed promising results in its Phase 1/2 trial, demonstrating a favorable safety profile in combination with cemiplimab. The study included 64 patients in the dose expansion cohort, with 41 patients having prior PD-(L)1 resistance.Financial highlights include cash position of $28.6 million as of June 30, 2025, expected to fund operations into Q2 2026. The company reported a reduced net loss of $4.9 million compared to $7.1 million in Q2 2024, with decreased R&D expenses of $2.5 million and G&A expenses of $2.7 million.Full data from the Phase 1/2 dose expansion cohort is expected by year-end 2025, with upcoming presentation at ESMO Congress 2025 in October.

#SNSE Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SNSE/sensei-biother...

Sensei Bio's 1:20 Reverse Split Slashes Outstanding Shares from 25M to 1.3M - What Investors Must Know Critical reverse split reduces 25.2M shares to 1.3M, effective June 16. See how this corporate action impacts your SNSE holdings. Get complete details.

#SNSE Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

www.stocktitan.net/news/SNSE/sensei-biother...

Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients Phase 1/2 trial completes enrollment with 63 patients. Promising data shows extended benefits in resistant cancers. Cash runway into Q2 2026. See full results.

#SNSE Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

www.stocktitan.net/news/SNSE/sensei-biother...

NEWS: ( NASDAQ: #SNSE ) Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors Clinical trial reveals 14% response rate in resistant tumors, marking significant breakthrough. Company reports streamlined operations with extended cash runway into 2026.

#SNSE Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

www.stocktitan.net/news/SNSE/sensei-biother...

Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed New cancer immunotherapy achieves triple the expected response rate in PD-(L)1 resistant tumors, with complete response in Merkel Cell Carcinoma. Full analysis inside.

#SNSE Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

www.stocktitan.net/news/SNSE/sensei-biother...

Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study Sensei Biotherapeutics' solnerstotug demonstrates strong tolerability and best-in-class pharmacokinetics in advanced tumor trial. Key data expected Q2 2025, with funding secured through 2026.

#SNSE Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

www.stocktitan.net/news/SNSE/sensei-biother...

#SNSE Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/SNSE/sensei-biother...